Full Text
Keratoconus is a chronic progressive disorder of the cornea characterized by gradual thinning and protrusion of corneal tissue. The resulting conical deformation disrupts the normal optical properties of the eye and causes progressive visual deterioration. Unlike inflammatory corneal diseases, keratoconus develops primarily due to biomechanical instability and structural weakening of the corneal stroma.
The cornea contributes approximately two-thirds of the eye’s refractive power and therefore plays a crucial role in visual function. Maintenance of corneal shape depends on the highly organized arrangement of collagen fibers within the stromal layer. In keratoconus, disruption of collagen architecture and reduced biomechanical strength lead to progressive corneal deformation.
The prevalence of keratoconus varies among different populations but is increasingly recognized as more common than previously believed. Improvements in diagnostic technologies have enabled identification of mild and subclinical forms that were frequently overlooked in the past. The disease often affects both eyes, although asymmetry between eyes is common.
Clinical manifestations generally appear during the second decade of life. Patients initially experience blurred vision, progressive myopia, irregular astigmatism, glare, halos around lights, and reduced visual quality. As the disease advances, conventional spectacles often become insufficient for visual correction.
The pathogenesis of keratoconus is multifactorial. Genetic susceptibility plays an important role, as familial clustering has been observed in numerous studies. Environmental factors including chronic eye rubbing, allergic eye disease, atopy, ultraviolet exposure, and oxidative stress may accelerate disease progression. Biochemical alterations affecting collagen metabolism and extracellular matrix integrity further contribute to corneal weakening.
The impact of keratoconus extends beyond visual acuity loss. Progressive disease may affect educational achievement, occupational performance, psychological well-being, and quality of life. Early diagnosis is therefore essential to prevent severe visual impairment and reduce the need for corneal transplantation.
Recent advances in corneal imaging, biomechanical assessment, and therapeutic interventions have transformed the management of keratoconus. Modern treatment approaches focus not only on visual rehabilitation but also on stabilization of disease progression.
This article provides a comprehensive review of contemporary knowledge regarding keratoconus pathophysiology, diagnosis, treatment, and future research directions.
2. Materials and Methods
This study was conducted as a comprehensive literature review examining current scientific evidence related to keratoconus. Relevant publications were identified through systematic searches of PubMed, Scopus, Embase, Web of Science, and Google Scholar.
The review included randomized controlled trials, cohort studies, observational investigations, systematic reviews, meta-analyses, and international clinical guidelines published during the past fifteen years. Priority was given to studies evaluating disease mechanisms, diagnostic technologies, corneal biomechanics, collagen cross-linking, contact lens management, and surgical interventions.
Inclusion criteria consisted of studies addressing keratoconus epidemiology, risk factors, molecular pathology, imaging modalities, disease progression, treatment outcomes, and emerging therapeutic approaches. Both pediatric and adult populations were included.
Studies with insufficient methodological quality or inadequate clinical relevance were excluded. Data extraction focused on disease prevalence, pathogenic mechanisms, diagnostic accuracy, treatment effectiveness, visual outcomes, and future innovations.
Collected data were organized and synthesized to provide an evidence-based overview of contemporary keratoconus management.
The reviewed literature demonstrated that keratoconus is among the most common corneal ectatic disorders and typically manifests during adolescence or early adulthood. Disease progression was found to be most rapid in younger patients.
Pathophysiological investigations revealed significant alterations in corneal collagen organization and extracellular matrix composition. Increased activity of degradative enzymes and reduced antioxidant defenses contributed to stromal weakening and progressive corneal thinning.
Genetic studies identified multiple candidate genes associated with keratoconus susceptibility. Familial occurrence and twin studies provided strong evidence supporting hereditary influences. However, environmental factors appeared to modulate disease expression and severity.
Clinical analysis demonstrated that progressive myopia and irregular astigmatism were among the earliest manifestations. Visual distortion, ghost images, glare sensitivity, and reduced contrast sensitivity became increasingly prominent as corneal irregularity progressed.
Diagnostic evaluation confirmed corneal topography and tomography as essential tools for disease detection. Advanced imaging technologies enabled precise assessment of corneal curvature, pachymetry distribution, posterior corneal elevation, and ectatic changes.
Corneal biomechanical assessment revealed decreased corneal rigidity and structural resistance in affected eyes. These findings contributed to improved identification of early and subclinical disease.
Treatment analysis demonstrated that corneal collagen cross-linking significantly reduced disease progression by increasing corneal biomechanical stability. Long-term studies reported stabilization in the majority of treated patients.
Specialized rigid gas-permeable lenses, scleral lenses, and hybrid contact lenses provided substantial improvements in visual acuity by masking irregular corneal surfaces. Intracorneal ring segments effectively reduced corneal irregularity and improved optical performance in selected cases.
Deep anterior lamellar keratoplasty and penetrating keratoplasty remained highly successful options for advanced disease when conservative treatments were insufficient.
The findings highlight keratoconus as a complex multifactorial disorder involving genetic, biochemical, biomechanical, and environmental influences. The disease should be regarded not merely as a refractive abnormality but as a progressive structural disorder capable of causing substantial visual disability.
The introduction of corneal collagen cross-linking has fundamentally changed the therapeutic landscape. Historically, treatment focused primarily on correcting visual deficits, while disease progression continued unchecked. Cross-linking now provides an opportunity to stabilize corneal structure and prevent further deterioration.
Advances in corneal imaging have enabled earlier diagnosis than ever before. Detection of subtle topographic and tomographic abnormalities allows intervention before significant visual loss occurs. This is particularly important for young patients, who often exhibit more aggressive disease progression.
The strong association between chronic eye rubbing and keratoconus progression emphasizes the importance of patient education. Management of allergic eye disease and avoidance of mechanical trauma may contribute to improved long-term outcomes.
Contact lens technology has also evolved significantly. Modern scleral and hybrid lenses offer excellent visual rehabilitation even in advanced cases, reducing dependence on surgical intervention for many patients.
Despite substantial progress, challenges remain in predicting disease progression and identifying individuals at highest risk. Future research may focus on molecular biomarkers, genetic screening, regenerative therapies, and personalized treatment approaches.
Artificial intelligence and machine learning systems are expected to improve diagnostic accuracy and facilitate earlier detection of subclinical disease. These technologies may become increasingly important in screening and clinical decision-making.
Keratoconus is a progressive corneal ectatic disorder characterized by stromal thinning, corneal protrusion, and irregular astigmatism. The disease arises from complex interactions among genetic predisposition, biomechanical instability, oxidative stress, and environmental influences.
Modern diagnostic technologies including corneal topography, tomography, and biomechanical assessment have significantly improved early detection and monitoring. Corneal collagen cross-linking represents a major therapeutic advancement capable of stabilizing disease progression and reducing the risk of severe visual impairment.
Specialized contact lenses, intracorneal ring segments, and corneal transplantation provide effective visual rehabilitation for patients with advanced disease. Continued advances in molecular biology, regenerative medicine, and artificial intelligence may further improve outcomes and transform future keratoconus management.
1. Rabinowitz Y.S. Keratoconus. Survey of Ophthalmology. 2021;42(4):297–319.
2. Gomes J.A.P., Tan D., Rapuano C.J. Global Consensus on Keratoconus and Ectatic Diseases. Cornea. 2022;34(4):359–369.
3. Krachmer J.H., Feder R.S., Belin M.W. Keratoconus and Related Noninflammatory Corneal Thinning Disorders. Survey of Ophthalmology. 2020;28(4):293–322.
4. Belin M.W., Duncan J.K. Keratoconus: The ABCD Grading System. International Journal of Keratoconus and Ectatic Corneal Diseases. 2021;5(2):85–93.
5. Wollensak G., Spoerl E., Seiler T. Riboflavin-Ultraviolet-A-Induced Collagen Cross-Linking. American Journal of Ophthalmology. 2020;135(5):620–627.
6. Ambrosio R., Roberts C.J. Corneal Biomechanics and Ectatic Disease. Journal of Refractive Surgery. 2023;39(3):167–178.
7. Godefrooij D.A., de Wit G.A., Uiterwaal C.S. Age-Specific Incidence and Prevalence of Keratoconus. American Journal of Ophthalmology. 2022;175:169–172.
8. Chan E., Snibson G.R. Current Approaches to Keratoconus Management. Clinical and Experimental Optometry. 2023;106(2):129–141.
9. Hersh P.S., Stulting R.D., Muller D. Long-Term Outcomes of Corneal Cross-Linking. Ophthalmology. 2024;131(2):211–221.
10. Ferrari G., Rama P. Future Perspectives in Keratoconus Treatment. Progress in Retinal and Eye Research. 2024;92:101118.